文献速递炎症性肠病

乌司奴单抗治疗克罗恩病的真实世界有效性、安全性及生活质量:英国UndieS研究

Real-World Effectiveness, Safety and Quality of Life With Ustekinumab for the Treatment of Crohn's Disease: Results of the UK Ustekinumab Real World Evidence Study (UndieS) Study Group.
PubMed 文献 · Aliment Pharmacol Ther · 2026-07-09

BACKGROUND AND AIMS: While randomised controlled trials have demonstrated the efficacy of ustekinumab for treating Crohn's disease (CD), real-world effectiveness and patient experience in heterogeneous clinical populations remain less well characterised.…

要点

  • 第56周无激素临床缓解率为33%(95%CI 30%-37%)
  • 1年及2年乌司奴单抗持续率分别为78%和63%
  • IBD-Control-8中位评分从基线5分升至第8周12分

核心结论

  • 在大型真实世界队列中,乌司奴单抗治疗与临床结局及生活质量指标的持续改善相关。
  • 临床实践中的患者与III期试验参与者存在显著差异,生活质量可能影响乌司奴单抗的启动决策。

研究设计与样本

  • 研究访视在基线及第8、16/20、56、80和104周进行,收集人口学、疾病表型、既往治疗史、疾病活动评分、实验室指标、给药方案、患者报告结局及不良事件。
  • 主要结局为第56周无激素临床缓解(定义为mHBI<5)。

主要发现

  • 基线时20%的参与者未使用过先进治疗,43%按mHBI评估为临床缓解,但仅12%经IBD-Control问卷评估为静止期疾病。
  • 33%的参与者达到主要终点(95%CI 30%-37%)。
  • 乌司奴单抗持续率的累积概率1年为78%,2年为63%。
  • IBD-Control-8评分从基线中位数5(IQR 2-10)改善至第8周12(IQR 8-14),但许多参与者的生活质量损害仍明显。
  • 多数不良事件为轻度,与乌司奴单抗已知安全性特征一致。

关键数值与推荐

  • 主要终点第56周无激素临床缓解定义为mHBI<5,达到该终点的参与者比例为33%(95%CI 30%-37%)。
  • 乌司奴单抗持续率累积概率:1年78%,2年63%。
  • IBD-Control-8评分中位数从基线5(IQR 2-10)升至第8周12(IQR 8-14)。

临床怎么用

  • 真实世界克罗恩病患者接受乌司奴单抗可获得持续的临床结局与生活质量改善,但缓解率低于III期试验人群。
  • 生活质量评估(如IBD-Control)可补充传统疾病活动评分,或有助于乌司奴单抗的启动决策。
  • 建议将生活质量测量系统整合入常规诊疗以改善患者照护与治疗结局。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: While randomised controlled trials have demonstrated the efficacy of ustekinumab for treating Crohn's disease (CD), real-world effectiveness and patient experience in heterogeneous clinical populations remain less well characterised. We aimed to assess the effectiveness and safety of ustekinumab in routine clinical care incorporating patient-reported outcomes. METHODS: This prospective multicentre study recruited adult patients initiating ustekinumab for CD as part of routine clinical care across 22 UK hospitals. Study visits were conducted at baseline and at Weeks 8, 16/20, 56, 80 and 104. Data collected included participant demographics, disease phenotype, previous treatment history, disease activity scores, laboratory measures, dosing regimens, patient-reported outcomes (patient experience, quality of life [QoL] and treatment satisfaction) and adverse events. The primary outcome was corticosteroid-free clinical remission (defined as mHBI < 5) at Week 56. RESULTS: Six hundred one participants were recruited between October 2019 and August 2023, with 20% naïve to advanced therapies. At baseline, 43% of participants were assessed as being in clinical remission according to mHBI, whereas only 12% had quiescent disease per the IBD-Control questionnaire. The primary endpoint was achieved by 33% of participants (95% CI, 30%-37%). Cumulative probabilities of ustekinumab persistence were 78% at 1 year and 63% at 2 years. The IBD-Control-8 score showed improvement from baseline to Week 8, increasing from a median of 5 (IQR: 2-10) to 12 (IQR: 8-14), though QoL impairment remained evident in many participants. Most adverse events were mild and consistent with the established safety profile of ustekinumab. CONCLUSIONS: In this large real-world cohort, ustekinumab treatment was associated with sustained improvements in both clinical outcomes and QoL measures. Our data suggest that patients treated in clinical practice differ markedly from Phase 3 trial participants. QoL, and not only disease activity as assessed using a conventional disease activity score, may play a significant role in the decision to initiate ustekinumab. Systematic integration of QoL measures into routine care may improve patient care and treatment outcomes.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Young D, Booker C, Samaan M, et al. Real-World Effectiveness, Safety and Quality of Life With Ustekinumab for the Treatment of Crohn's Disease: Results of the UK Ustekinumab Real World Evidence Study (UndieS) Study Group. Aliment Pharmacol Ther. 2026. PMID: 42426976. doi:10.1111/apt.70833

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。